FDA Approval Process

In Detail

The FDA approval process is the multi-step regulatory pathway that a new drug, biologic, or medical device must complete before it can be marketed and sold in the United States. The process begins with preclinical research — laboratory and animal studies that establish basic safety and biological activity. If preclinical results are promising, the sponsor files an Investigational New Drug (IND) application with the FDA, which must be approved before human testing can begin. The drug then progresses through Phase 1, Phase 2, and Phase 3 clinical trials, each generating increasingly comprehensive safety and efficacy data. After successful Phase 3 trials, the sponsor submits a New Drug Application (NDA) for drugs or a Biologics License Application (BLA) for biologics. The NDA/BLA includes all preclinical and clinical data, manufacturing information, proposed labeling, and a comprehensive safety analysis. FDA reviewers — including physicians, statisticians, chemists, and pharmacologists — evaluate the submission, which typically takes 10-12 months for a standard review or 6-8 months for a priority review. The FDA may convene an advisory committee of independent experts to discuss the application at a public meeting. The entire process from preclinical research to approval averages 10-15 years and costs an estimated $1-2 billion. The FDA can grant expedited pathways — such as Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review — for treatments addressing serious conditions with unmet medical needs. After approval, Phase 4 post-marketing studies continue to monitor the drug's safety in real-world use.